First randomised trial tests criteria used to diagnose heart attack

August 28, 2018

Munich, Germany - 28 Aug 2018: Results of the first randomised trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 20181 and published in The Lancet.

Professor Nicholas Mills, principal investigator, University of Edinburgh, UK, said: "These results are controversial because they suggest that the Universal Definition of Myocardial Infarction needs to move away from binary thresholds to diagnose and treat patients with myocardial infarction. It is now up to the research community to find a superior approach."

Myocardial infarction is one of the leading causes of death worldwide. It is diagnosed with a combination of clinical history, electrocardiogram and a rise or fall in the concentration of cardiac troponin,2,3 a protein released into the blood when the heart muscle is injured. The Universal Definition of Myocardial Infarction recommends that any increase in troponin above the 99th centile of a healthy reference population should be used as one of the diagnostic criteria.2,3

The High-STEACS trial4 is the first randomised trial to evaluate whether the introduction of a high-sensitivity cardiac troponin I assay with a 99th centile diagnostic threshold would reduce subsequent myocardial infarction or cardiovascular death at one year in patients with suspected acute coronary syndrome.

The trial included all patients presenting with suspected acute coronary syndrome to the emergency department at ten hospitals in Scotland, UK. All patients had measurements of cardiac troponin I using a contemporary assay as the standard of care and a high-sensitivity assay at presentation and six or 12 hours afterwards. During a six-month validation phase, clinical decisions were guided by the contemporary cardiac troponin I assay using the existing diagnostic threshold. Hospitals were then randomly allocated to early or late implementation of the high-sensitivity assay to guide clinical decisions using the 99th centile. Registries were used to record the primary outcome of myocardial infarction or cardiovascular death at one year.

The rate of the primary outcome was compared in patients reclassified using the high-sensitivity assay (above the 99th centile but below the contemporary assay threshold) before and after implementation of the high-sensitivity assay for clinical decision making.

A total of 48,282 patients were enrolled. The average age was 61 years and 47% were women. Just over one-fifth (10,360; 22%) had high-sensitivity cardiac troponin I concentrations above the 99th centile. The high-sensitivity assay reclassified 1,771 (17%) patients with myocardial injury or infarction not identified by the standard assay. Of those, less than one third had a final diagnosis of myocardial infarction.

In those reclassified, the primary outcome occurred in 105 of 720 (14.6%) patients in the validation phase and 131 of 1,051 (12.5%) patients in the implementation phase. The adjusted odds ratio for the implementation versus validation phase was 1.10 (95% confidence interval 0.75-1.61, p=0.620).

Professor Mills said: "The trial found that implementation of a high-sensitivity cardiac troponin I assay using the 99th centile as the diagnostic threshold increased the frequency of diagnosing myocardial injury or infarction. However, use of this method to help diagnose and treat patients was not associated with lower rates of recurrent myocardial infarction or cardiovascular death at one year."

He continued: "The findings were surprising and initially disappointing. But it was encouraging that there was no evidence of misdiagnosis, inappropriate treatment, excess bleeding or harm. Indeed, the length of stay across the trial population was reduced by almost a third suggesting that use of the high-sensitivity test increased the confidence of clinicians to rule out heart disease, with benefits for health service providers."

Professor Mills noted that the trial was embedded within routine clinical assessment with hospitals as the unit of randomisation. "It included every patient evaluated using the test, thereby avoiding selection bias and ensuring that the findings are generalisable," he said.
Notes to editors

SOURCES OF FUNDING: This trial was funded by the British Heart Foundation. Abbott Laboratories provided cardiac troponin assay reagents, calibrators, and controls without charge.

DISCLOSURES: Anoop S.V. Shah and Andrew R. Chapman have received honoraria from Abbott Diagnostics. Nicholas L. Mills has received honoraria and consultancy from Abbott Diagnostics, Roche Diagnostics and Singulex.

TWITTER handle: @highSTEACS

References and notes

1 High-STEACS will be discussed during:2 Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567. doi: 10.1093/eurheartj/ehs184.

3 2018 ESC/ACCF/AHA/WHF Fourth Universal Definition of Myocardial Infarction. European Heart Journal. 2018. doi: 10.1093/eurheartj/ehy462.

4 High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary Syndrome (High-STEACS).

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2018

ESC Congress is the world's largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.

More information is available from the ESC Press Office at

European Society of Cardiology

Related Myocardial Infarction Articles from Brightsurf:

Treatment shows reduction in heart failure after myocardial infarction
Researchers at Baylor College of Medicine identified potential preventative therapies for heart failure after a significant heart attack.

The challenges of treating acute myocardial infarction due to variant angina
In a new publication from Cardiovascular Innovations and Applications; DOI, Wen-Yuan Ding, Jia-Min Li, Fei Zheng, Li-Li Wang, Xin-Yi Wei and Guo-Hua Li from Shandong Provincial Qianfoshan Hospital, Ji'nan, China, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, China and Shandong First Medical University, Tai'an, China consider the challenges of treating acute myocardial infarction due to variant angina.

WeChat group of chest pain center for patients with acute ST-segment elevation myocardial infarction
In a new publication from Cardiovascular Innovations and Applications; DOI, Liu Yue, Qin Zhu-Yun, Yang Xin, Tang Rong and Gao Ling-Yun from the The First Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the use of a social media platform (WeChat) to provide faster treatment and improve prognoses for a group of patients with acute ST-segment Elevation Myocardial Infarction.

Improved survival after obesity operation in patients with previous myocardial infarction
Researchers at Karolinska Institutet and Danderyd Hospital in Sweden have studied the risk of additional myocardial infarctions and early death in severely obese patients who undergo metabolic surgery following a myocardial event.

Researchers discover a cell type responsible for cardiac repair after infarction
The researcher of the Faculty of Science of the UMA Adrián Ruiz-Villalba, who is also member of the Andalusian Center for Nanomedicine and Biotechnology (BIONAND) and the Biomedical Research Institute of Malaga (IBIMA), is the first author of an international study that has identified the heart cells in charge of repairing the damage caused to this organ after infarction.

Discovery of cells that heal cardiac damage after infarction
Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction.

CHOP researchers find MIS-C associated with myocardial injury
Using sensitive parameters to assess cardiac function, researchers at Children's Hospital of Philadelphia (CHOP) have found that cardiac involvement in multisystem inflammatory syndrome in children (MIS-C) differs from Kawasaki disease (KD) and is associated with myocardial injury.

Heart attack modeled with human stem cells
A model of ischemic heart disease was developed using human induced pluripotent stem cells (hiPSC).

The relationship between lifetime drinking and non-fatal acute myocardial infarction
New research from the Prevention Research Center of the Pacific Institute for Research and Evaluation suggests that the impact of alcohol consumption on coronary heart disease may be underestimated.

The relationship between mean platelet volume and in-hospital mortality in geriatric patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Read More: Myocardial Infarction News and Myocardial Infarction Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to